EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RNF7‐Mediated ROS Targets Malignant Phenotype and Radiotherapy Sensitivity in Glioma With Different IDH1 Genotypes

Yiran Tao, Zimin Shi, Xianyin Liang, Yuqian Zheng, Lirui Dai, Xiang Li, Zian Li, Wulong Liang, Gaojie Bai, Hao Li, Yuan Lyu, Junqi Li und 6 weitere

Molecular Carcinogenesis · 2025-04 · 64 (4) · 652-667

DOI: 10.1002/mc.23876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 09.01.2025. Verfasst von Yiran Tao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, The People's Republic of China. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Reactive Oxygen Species, Radiation Tolerance. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research was funded by the National Natural Science Foundation of China (No. 81972361, 82303029, 82473349, and 82403709); Henan Province key research and…, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNF7 (Ring Finger Protein 7) is a key component of CRLs (Cullin‐RING‐type E3 ubiquitin ligases) and has been found to possess intrinsic anti‐ROS capabilities. Aberrant expression of RNF7 has been observed in various tumor types and is known to significantly influence tumor initiation and progression. However, the specific role of RNF7 in glioblastoma remains unclear. IDH (isocitrate dehydrogenase) mutations, which induce metabolic reprogramming and result in notable heterogeneity among glioma with different IDH genotypes. Through analysis of public glioma databases, we identified a high expression of RNF7 in glioma and its correlation with patient prognosis. Moreover, we observed variations in RNF7 expression and its association with patient outcomes under different treatment modalities among different IDH genotypes. In this study, we demonstrated the critical role of RNF7 in the malignant phenotype of IDH1‐mutant glioma and its contribution to radiation resistance. Subsequent functional enrichment analysis of RNF7 in glioma, coupled with validation through cellular experiments, confirmed its significant involvement in maintaining redox balance. Our findings suggest that RNF7 exerts a buffering effect against radiation‐induced oxidative stress and counterbalances the redox stress induced by IDH1 mutation through its anti‐ROS activity. Additionally, our follow‐up investigations revealed that the upregulation of RNF7 after radiation exposure and in IDH1‐mutant glioma cells is induced by ROS. Collectively, our study underscores the potential of RNF7 as a molecular biomarker in glioma. Elevated RNF7 expression often indicates a heightened metabolic resilience in glioma, leading to resistance against radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseGliomaReactive Oxygen SpeciesRadiation ToleranceUbiquitin-Protein LigasesBrain NeoplasmsHumansMutationPrognosisCell Line, TumorGene Expression Regulation, NeoplasticGenotypePhenotypeOxidative StressBiomarkers, Tumor

Stichwörter der Autor:innen

IDH1 mutationRNF7ROSgliomaradiotherapy

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanReactive Oxygen SpeciesUbiquitin-Protein LigasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, The People's Republic of China.
  • Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, The People's Republic of China.
  • Department of Neurosurgery, Pituitary Adenoma Multidisciplinary Center, West China Hospital of Sichuan University, Chengdu, Sichuan, The People's Republic of China.
  • Henan International Joint Laboratory of Glioma Metabolism and Microenvironment Research, Zhengzhou, Henan, The People's Republic of China.
  • Maternal and Child Neurological Disorders International Joint Research Center, Zhengzhou, Henan, The People's Republic of China.
  • Tianjian Laboratory of Advanced Biomedical Sciences, School of life sciences, Zhengzhou University, Zhengzhou, Henan, The People's Republic of China.

ORCID-Profile: Xinjun Wang

Förderung

  • This research was funded by the National Natural Science Foundation of China (No. 81972361, 82303029, 82473349, and 82403709); Henan Province key research and…
  • National Natural Science Foundation of China

Zitieren

APA

Tao, Y., Shi, Z., Liang, X., Zheng, Y., Dai, L., Li, X., Li, Z., Liang, W., Bai, G., Li, H., Lyu, Y., Li, J., Zhang, T., Hu, W., Zhou, S., Shan, Q., Fu, X., & Wang, X. (2025). RNF7‐Mediated ROS Targets Malignant Phenotype and Radiotherapy Sensitivity in Glioma With Different IDH1 Genotypes. Molecular Carcinogenesis, 64(4), 652-667. https://doi.org/10.1002/mc.23876

Vancouver

Tao Y, Shi Z, Liang X, Zheng Y, Dai L, Li X, et al. RNF7‐Mediated ROS Targets Malignant Phenotype and Radiotherapy Sensitivity in Glioma With Different IDH1 Genotypes. Molecular Carcinogenesis. 2025;64(4):652-667. doi:10.1002/mc.23876

BibTeX
@article{Tao2025,
  author = {Tao, Yiran and Shi, Zimin and Liang, Xianyin and Zheng, Yuqian and Dai, Lirui and Li, Xiang and Li, Zian and Liang, Wulong and Bai, Gaojie and Li, Hao and Lyu, Yuan and Li, Junqi and Zhang, Tao and Hu, Weihua and Zhou, Shaolong and Shan, Qiao and Fu, Xudong and Wang, Xinjun},
  title = {RNF7‐Mediated ROS Targets Malignant Phenotype and Radiotherapy Sensitivity in Glioma With Different IDH1 Genotypes},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  volume = {64},
  number = {4},
  pages = {652--667},
  doi = {10.1002/mc.23876}
}
Kostenlos starten →